What You Ought to Know:
– myTomorrows, a well being expertise firm that connects sufferers with all potential pre-approval therapies, immediately introduced the shut of a $29 million financing with Avego. Avego’s development fairness funding will gasoline the worldwide growth of myTomorrows’ built-in pharma options to make rising therapies extra equitable and accessible for sufferers globally.
– With greater than 300 million sufferers worldwide dealing with situations with out authorised therapy choices, and over 10,000 therapies at present in growth or awaiting approval – myTomorrows is addressing certainly one of healthcare’s most pressing challenges: bridging the hole between scientific development and affected person entry to pre-approval therapies, which embrace scientific trials and expanded entry applications (EAPs).
myTomorrows Expands International AI Platform to Speed up Affected person Entry to Pre-Approval Therapies
myTomorrows is redefining how sufferers and physicians entry investigational therapies by bridging the hole between scientific growth and real-world care. The worldwide HealthTech firm operates a unified, multi-stakeholder platform that connects sufferers, physicians, trial websites, and BioPharma companions—simplifying entry to pre-approval therapies by means of the facility of AI and knowledgeable human navigation. By bringing transparency, coordination, and perception to the therapy discovery course of, myTomorrows is accelerating world entry to progressive therapies whereas advancing data-driven drug growth.
The newest funding will gasoline the corporate’s worldwide growth and additional improve its AI-driven world platform—deepening integration with BioPharma companions to shorten scientific growth timelines, enrich real-world proof era, and strengthen regulatory perception. “This funding marks a pivotal step in our journey to present each affected person, irrespective of the place they stay, a good shot at tomorrow’s therapies,” stated Michel van Harten, CEO of myTomorrows. “Avego’s deep life sciences experience, particularly in BioPharma, might be instrumental as we scale our platform and broaden our world affect.”
At the moment, myTomorrows operates the world’s most complete AI-powered platform for pre-approval therapies, having already supported greater than 16,900 sufferers throughout 133 international locations. The platform empowers sufferers and clinicians by means of knowledgeable steering, personalised therapy matching, and seamless entry to each scientific trials and expanded entry applications. For BioPharma companions, it gives end-to-end companies in trial recruitment, expanded entry administration, and real-world information seize, whereas trial websites profit from unified referral programs with real-time monitoring and enhanced visibility.
By connecting each stakeholder within the therapy ecosystem, myTomorrows is laying the muse for a brand new period of world healthcare entry—one outlined by AI-enabled precision, adaptive regulation, and empowered sufferers. Embedded throughout well being programs worldwide, its platform offers unbiased, actionable pathways to rising therapies, making certain that medical breakthroughs attain those that want them most—precisely when it issues.
